Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03600064
Other study ID # MIUD
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date July 1, 2019
Est. completion date September 1, 2020

Study information

Verified date September 2020
Source Assiut University
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Intrauterine devices are the most common used method of contraception in the world, mostly in developing countries, because they offer long-term, reversible and relatively safe contraception. At present, 50% of intrauterine devices users are women of reproductive age and most of them are requesting Intrauterine device removal to regain their fertility. In general, an intrauterine device should be removed during menses or preferably immediate after menses because intrauterine device removal is usually easy because the cervix is still soft.

The intrauterine device is usually removed by firmly grasping the threads at the external os; traction should be applied away from the cervix. If resistance is present, the removal should be stopped until it is determined why the intrauterine device is not moving. Some deeply embedded intrauterine device may need to be removed by hysteroscope [4].

In practice, many women, however, have an intolerable pain during intrauterine device removal and some of them requesting painkiller or even anesthesia to allow the physician to remove it. Cervical hardening and adhesions are the major factors making IUD removal difficult especially in post-menopausal women.

Insertion and removal of IUD in nulliparous women is possible but it may carry more pain, more difficulty than in parous women. We think that this problem is also present in women has no vagina delivery before. So, the intrauterine device removal actually has some difficulty or pain in the nulliparous women, women delivered by elective caesarian section or postmenopausal women.

Many medical agents for cervical ripening prior to the removal have been emerged like misoprostol. Misoprostol is commonly used for cervical ripening in the first and second trimester miscarriage and prior intrauterine devices insertion. The use of vaginal misoprostol before intrauterine device insertion in women who had never delivered vaginally before may increase the ease and success of insertion with pain felt during the procedure .

However and up to our knowledge; no studies had been reported the effect of misoprostol on removal pain in women delivered only by elective cesarean section.


Recruitment information / eligibility

Status Completed
Enrollment 80
Est. completion date September 1, 2020
Est. primary completion date July 1, 2020
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Female
Age group 18 Years to 45 Years
Eligibility Inclusion Criteria:

1. Aged 18-45 years

2. Menstruating women

3. Nonpregnant women

4. Delivered before only by elective cesarean section

5. Women who did not receive any analgesics in the 24 h prior to Intrauterine device removal.

6. Using copper 380 A Intrauterine device for contraception only

7. Requesting Intrauterine device removal for returning of fertility

Exclusion Criteria:

1. Women with allergy to misoprostol or any medical disease that contraindicates its use

2. Ultrasonographic evidence of displaced Intrauterine device.

3. Women who will refuse to participate in the study.

4. Women who had any other type of Intrauterine device.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Misoprostol
the women will be received two tablets of misoprostol 400 mcg vaginally before IUD removal (Misotac®; Sigma Pharma, SAE, Egypt).

Locations

Country Name City State
Egypt Women Health Hospital - Assiut university Assiut

Sponsors (1)

Lead Sponsor Collaborator
Assiut University

Country where clinical trial is conducted

Egypt, 

Outcome

Type Measure Description Time frame Safety issue
Primary The degree of pain perception immediate after intrauterine device removal measured by Visual analogue scale visual analogue scale from 0 to 10 score (0 means no pain, 10 means maximum pain) 1 minute
See also
  Status Clinical Trial Phase
Completed NCT03686085 - Vaginal Dinoprostone Administration Prior to a T380A Intrauterine Device Insertion in Nulliparous Women. Phase 3
Recruiting NCT05550064 - Structured Contraceptive Counseling During Pregnancy N/A
Recruiting NCT06179095 - The Effect of Virtual Reality on Anxiety During Intrauterine Device Insertion N/A
Completed NCT03383432 - Intrauterine Device Insertion: a Step for High Satisfaction N/A
Completed NCT05556421 - Can Uterocervical Angle Predict the Displacement of Copper Intrauterine Devices (T-Cu 380A)
Completed NCT04045548 - Vaginal Dinoprostone Administration Prior to Insertion Levonorgestrel-releasing Intrauterine System in Women With no Previous Vaginal Delivery Phase 4
Completed NCT03870711 - 10% Lidocaine Spray for Intrauterine Device Insertion Phase 4
Completed NCT02898831 - Cold Compress for Pain Associated With Intrauterine Device Insertion N/A